TLE4 and gastric cancer: Further analyses using the UALCAN database (Chandrashekar et al., 2017; Chandrashekar et al., 2022) consistently showed reduced TLE4 expression at all stages (I-IV) of GC, suggesting that low TLE4 expression may serve as a potential predictive marker for disease progression (Figure 4C).